| scholarly article | Q13442814 |
| review article | Q7318358 |
| P356 | DOI | 10.1093/CLINIDS/15.2.346 |
| P698 | PubMed publication ID | 1381621 |
| P2093 | author name string | J. B. Robbins | |
| R. Schneerson | |||
| C. Chu | |||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | antibody | Q79460 |
| polysaccharide | Q134219 | ||
| lipopolysaccharide | Q421804 | ||
| vaccine | Q134808 | ||
| P304 | page(s) | 346-361 | |
| P577 | publication date | 1992-08-01 | |
| P1433 | published in | Clinical Infectious Diseases | Q5133764 |
| P1476 | title | Hypothesis for vaccine development: protective immunity to enteric diseases caused by nontyphoidal salmonellae and shigellae may be conferred by serum IgG antibodies to the O-specific polysaccharide of their lipopolysaccharides | |
| P478 | volume | 15 |
| Q35916527 | Acute, infectious diarrhea among children in developing countries |
| Q64948328 | Age-related efficacy of Shigella O-specific polysaccharide conjugates in 1-4-year-old Israeli children. |
| Q38284501 | An assessment of enterotoxigenic Escherichia coli and Shigella vaccine candidates for infants and children |
| Q35428887 | Analysis of human monoclonal antibodies elicited by vaccination with a Cryptococcus neoformans glucuronoxylomannan capsular polysaccharide vaccine. |
| Q92801042 | Characterization and immunogenicity of a Shigella flexneri 2a O-antigen bioconjugate vaccine candidate |
| Q92487093 | Classical and novel strategies to develop a Shigella glycoconjugate vaccine: from concept to efficacy in human |
| Q36844719 | Clinical trials of Shigella vaccines: two steps forward and one step back on a long, hard road |
| Q35425792 | Comparative immunogenicity of conjugates composed of Escherichia coli O111 O-specific polysaccharide, prepared by treatment with acetic acid or hydrazine, bound to tetanus toxoid by two synthetic schemes. |
| Q42413095 | Comparative role of immunoglobulin A in protective immunity against the Bordetellae |
| Q35771562 | Comparison of conjugates composed of lipopolysaccharide from Shigella flexneri type 2a detoxified by two methods and bound to tetanus toxoid |
| Q50089466 | Conjugation of tetanus toxoid with Salmonella typhimurium PTCC 1735 O-specific polysaccharide and its effects on production of opsonizing antibodies in a mouse model |
| Q38683902 | Correlates of protection for enteric vaccines |
| Q35227169 | Detection of antibodies to Shigella lipopolysaccharide in urine after natural Shigella infection or vaccination |
| Q37643320 | Development and preclinical evaluation of a trivalent, formalin-inactivated Shigella whole-cell vaccine. |
| Q54572055 | Double-blind vaccine-controlled randomised efficacy trial of an investigational Shigella sonnei conjugate vaccine in young adults. |
| Q35955978 | Effect of the nonreducing end of Shigella dysenteriae type 1 O-specific oligosaccharides on their immunogenicity as conjugates in mice |
| Q30443288 | Enteric infections, diarrhea, and their impact on function and development |
| Q37032264 | Evaluation of immunogenicity and protective efficacy of orally delivered Shigella type III secretion system proteins IpaB and IpaD. |
| Q37633069 | Functional and Antigen-Specific Serum Antibody Levels as Correlates of Protection against Shigellosis in a Controlled Human Challenge Study |
| Q40429740 | Future vaccine development at NICHD. |
| Q99616552 | Immune Response Characterization after Controlled Infection with Lyophilized Shigella sonnei 53G |
| Q40283278 | Immunization with the conjugate vaccine Vi-CRM₁₉₇ against Salmonella typhi induces Vi-specific mucosal and systemic immune responses in mice |
| Q37640115 | Inactivated and subunit vaccines to prevent shigellosis |
| Q38140038 | Increasing rates of Salmonella Paratyphi A and the current status of its vaccine development |
| Q37720658 | Intradermal delivery of Shigella IpaB and IpaD type III secretion proteins: kinetics of cell recruitment and antigen uptake, mucosal and systemic immunity, and protection across serotypes |
| Q37163698 | Monoclonal Antibodies to Shigella Lipopolysaccharide Are Useful for Vaccine Production. |
| Q41630631 | Nasal immunization of mice with AFCo1 or AFPL1 plus capsular polysaccharide Vi from Salmonella typhi induces cellular response and memory B and T cell responses. |
| Q35844488 | O-specific [corrected] polysaccharide conjugate vaccine-induced [corrected] antibodies prevent invasion of Shigella into Caco-2 cells and may be curative |
| Q42549891 | Of four murine, anti-Shigella dysenteriae type 1 O-polysaccharide antibodies, three employ V-genes that differ extensively from those of the fourth |
| Q34064616 | Oligosaccharide-protein conjugates as vaccine candidates against bacteria |
| Q87281013 | Oral administration of live Shigella vaccine candidates in rhesus monkeys show no evidence of competition for colonization and immunogenicity between different serotypes |
| Q34003647 | Phase 1 and phase 2 studies of Salmonella enterica serovar paratyphi A O-specific polysaccharide-tetanus toxoid conjugates in adults, teenagers, and 2- to 4-year-old children in Vietnam |
| Q44891342 | Preparation of synthetic glycoconjugates as potential vaccines against Shigella flexneri serotype 2a disease |
| Q34545082 | Preparation, characterization, and immunological properties in mice of Escherichia coli O157 O-specific polysaccharide-protein conjugate vaccines |
| Q37105553 | Progress and pitfalls in Shigella vaccine research |
| Q35424942 | Protection against local Shigella sonnei infection in mice by parenteral immunization with a nucleoprotein subcellular vaccine |
| Q28343287 | Protein conjugates of synthetic saccharides elicit higher levels of serum IgG lipopolysaccharide antibodies in mice than do those of the O-specific polysaccharide from Shigella dysenteriae type 1 |
| Q41008205 | Purification and characterization of a Shigella conjugate vaccine, produced by glycoengineering Escherichia coli |
| Q38068954 | Recent progress towards development of a Shigella vaccine |
| Q92968346 | Role of antigen specific T and B cells in systemic and mucosal immune responses in ETEC and Shigella infections, and their potential to serve as correlates of protection in vaccine development |
| Q36842967 | Saccharide/protein conjugate vaccines for Bordetella species: preparation of saccharide, development of new conjugation procedures, and physico-chemical and immunological characterization of the conjugates. |
| Q39056494 | Safety and immunogenicity of a candidate bioconjugate vaccine against Shigella dysenteriae type 1 administered to healthy adults: A single blind, partially randomized Phase I study |
| Q102056730 | Safety and immunogenicity of a synthetic carbohydrate conjugate vaccine against Shigella flexneri 2a in healthy adult volunteers: a phase 1, dose-escalating, single-blind, randomised, placebo-controlled study |
| Q34006223 | Safety and immunogenicity of improved Shigella O-specific polysaccharide-protein conjugate vaccines in adults in Israel |
| Q35523144 | Safety and immunogenicity of investigational Shigella conjugate vaccines in Israeli volunteers |
| Q91881906 | Serum IgG antibodies to Shigella lipopolysaccharide antigens - a correlate of protection against shigellosis |
| Q34000330 | Strategy for cross-protection among Shigella flexneri serotypes |
| Q34521446 | Structural and serological specificities of Pasteurella haemolytica lipopolysaccharides. |
| Q33577920 | Synthesis and immunogenicity evaluation of Salmonella enterica serovar Paratyphi A O-specific polysaccharide conjugated to diphtheria toxoid |
| Q35548581 | Synthesis and immunological properties of Vi and di-O-acetyl pectin protein conjugates with adipic acid dihydrazide as the linker |
| Q52222815 | Synthesis of di- to penta-saccharides related to the O-specific polysaccharide of Shigella dysenteriae type 1, and their nuclear magnetic resonance study |
| Q71805493 | Synthesis of specifically deoxygenated disaccharide derivatives of the Shigella dysenteriae type 1 O-antigen |
| Q44367051 | Synthesis of the pentasaccharide related to the repeating unit of the antigen from Shigella dysenteriae type 4 in the form of its methyl ester 2-(trimethylsilyl)ethyl glycoside |
| Q73853185 | Synthesis of the tetrasaccharide related to the repeating unit of the antigen from Shigella dysenteriae type 5 |
| Q33607442 | Synthesis, characterization, and clinical evaluation of conjugate vaccines composed of the O-specific polysaccharides of Shigella dysenteriae type 1, Shigella flexneri type 2a, and Shigella sonnei (Plesiomonas shigelloides) bound to bacterial toxoid |
| Q37194696 | Synthesis, characterization, and immunogenicity in mice of Shigella sonnei O-specific oligosaccharide-core-protein conjugates |
| Q35505761 | Synthesis, characterization, and immunological properties in mice of conjugates composed of detoxified lipopolysaccharide of Salmonella paratyphi A bound to tetanus toxoid with emphasis on the role of O acetyls |
| Q24672570 | The O antigen enables Bordetella parapertussis to avoid Bordetella pertussis-induced immunity |
| Q38909275 | The Orchestra and Its Maestro: Shigella's Fine-Tuning of the Inflammasome Platforms. |
| Q34424977 | The structure of the Escherichia coli O148 lipopolysaccharide core region and its linkage to the O-specific polysaccharide. |
| Q34002272 | Treatment with succinic anhydride improves the immunogenicity of Shigella flexneri type 2a O-specific polysaccharide-protein conjugates in mice |
| Q40098097 | Vaccination with Shigella flexneri 2a conjugate induces type 2a and cross-reactive type 6 antibodies in humans but not in mice |
| Q33578045 | Vaccines against human diarrheal pathogens: current status and perspectives |
| Q36128243 | Vaccines based on the cell surface carbohydrates of pathogenic bacteria |
| Q91767150 | Vaccines for enteric diseases |
| Q79771810 | [Carbohydrates and vaccines: from purified polysaccharides to semi-synthetic glycoconjugate vaccines] |
Search more.